NASDAQ: XERSXeris Biopharma Holdings Inc Stock
$6.51-0.21 (-3.13%)
Updated Dec 5, 2025
XERS Price
$6.51
Fair Value Price
N/A
Market Cap
$1.08B
52 Week Low
$3.14
52 Week High
$10.08
P/E
-65.1x
P/B
-1,254.55x
P/S
5.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$266.14M
Earnings
-$15.64M
Gross Margin
84.6%
Operating Margin
5.26%
Profit Margin
-5.9%
Debt to Equity
-430.96
Operating Cash Flow
$11M
Beta
1.25
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
XERS Overview
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine XERS's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important XERS news, forecast changes, insider trades & much more!
XERS News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how XERS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
XERS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
XERS is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
XERS's Earnings (EBIT) of $13.99M... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more XERS due diligence checks available for Premium users.
Valuation
XERS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-65.1x
Industry
186.51x
Market
46.7x
XERS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1,254.55x
Industry
5.29x
XERS's financial health
Profit margin
Revenue
$74.4M
Net Income
$621.0k
Profit Margin
0.8%
XERS's Earnings (EBIT) of $13.99M... subscribe to Premium to read more.
Interest Coverage Financials
XERS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$370.2M
Liabilities
$371.1M
Debt to equity
-430.96
XERS's short-term assets ($224.02M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
XERS's long-term liabilities ($254.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
XERS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
XERS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$18.4M
Investing
-$71.0k
Financing
$13.9M
XERS's operating cash flow ($10.56M)... subscribe to Premium to read more.
Debt Coverage Financials
XERS vs Biotech Stocks
Xeris Biopharma Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.